Hong Kong Consumer Durables Stock News

Hua Hong Grace Semiconductor was recently added to the Hang Seng Index, following a period when chip makers climbed while major Chinese financial institutions faced capital raising plans. The index inclusion places Hua Hong Grace Semiconductor alongside Hong Kong’s largest constituents. This can influence how global funds treat its capacity expansion, mature-node focus, and domestic revenue concentration. With Hua Hong Grace Semiconductor now part of the Hang Seng Index, it is worth...

Legend Holdings reported half year 2026 results, with revenue of CNY 362,934.67 million and net income of CNY 2,229.75 million, alongside basic and diluted EPS from continuing operations of CNY 0.95. The wide gap between revenue and profit, even with higher earnings per share, highlights how cost control and business mix remain central to Legend Holdings' profitability story. With that jump in earnings per share now reported, we will examine how this may influence Legend Holdings' broader...

Lam Soon Hong Kong stock barely budged at HK$11.0 after the fresh numbers, yet the real story sits in the squeeze on profitability rather than the share price. A trailing P/E of 8.8x against higher industry and peer averages might look tempting, but a net profit margin of 5.8% compared with 6.3% a year earlier indicates that earnings power is under pressure. Layer a 4.36% dividend yield on top of free cash flow that has not comfortably covered those payouts, and the headline from these...

Rising odds of a Fed rate hike, gold holding near US$4,400, and fresh geopolitical risk in the Middle East are pulling money toward perceived havens and away from high-octane growth stories. That reshuffle creates both potential safety nets and potential traps. This piece walks through three precious metals stocks from our screener that appear especially exposed to these headlines, so you can decide which opportunities or risks deserve a closer look. The stocks covered below are just a small...

Lonking Holdings reported half year 2026 results, with sales of CNY 6,657.94 million and net income of CNY 773.07 million, and basic and diluted EPS from continuing operations of CNY 0.18 versus CNY 0.15 a year earlier. The combination of higher sales and net profit indicates that Lonking Holdings converted demand into improved earnings efficiency, which can sharpen management’s focus on capital allocation and future investment priorities. Next, attention turns to how this stronger first...

Shanghai Electric Group reported first half 2026 results, with sales of CNY 61,214.79 million, revenue of CNY 63,331.97 million, and net income of CNY 969.99 million, alongside basic and diluted EPS from continuing operations of CNY 0.062. The simultaneous increases in sales, revenue, net income, and earnings per share suggest Shanghai Electric Group converted higher activity into stronger profitability from its continuing operations. With Shanghai Electric Group posting higher earnings per...

Oil prices are jumping, Middle East supply routes are under threat and headlines about strikes on tankers and refineries are back on front pages. When energy becomes the story, capital often moves quickly, and sitting on the sidelines can feel risky if you do not understand who might benefit or struggle. This article breaks down three integrated oil and gas stocks exposed to this news, and why each one could matter for your portfolio decisions. The three stocks featured below are just a...

Ascletis Pharma reported a CNY 319.67 million net loss for the half year to June 30, 2026, while also advancing ASC30 into global Phase III trials for chronic weight management and diabetes across the U.S., Europe, and Canada. The firm’s inclusion in both the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs from September 7, 2026, opens its shares to a wider Mainland China investor pool and may influence how funding for its obesity portfolio is perceived. With Ascletis Pharma...

Minth Group Limited reported half year 2026 results with sales of CNY 13,408.35 million and net income of CNY 1,434.14 million, alongside basic earnings per share from continuing operations of CNY 1.235 and diluted earnings per share of CNY 1.22. The pairing of higher sales and net income with stronger earnings per share suggests operating efficiency gains within Minth Group's core business rather than only top line expansion. With Minth Group posting higher earnings per share from...

Qingdao Port International (SEHK:6198) has drawn fresh attention after releasing half year 2026 results that combined higher sales with slightly lower net income, along with a reduced ordinary interim dividend for shareholders. Qingdao Port International’s recent half year results and reduced interim dividend have come alongside a 6.60% 1 month share price return and a small 1 day rise to HK$7.345, while the 1 year total shareholder return of 13.05% sits within a much stronger 3 year total...

Insiders were net buyers of Shenguan Holdings (Group) Limited's ( HKG:829 ) stock during the past year. That is...

Kingboard Holdings stock reacts to higher interim dividend and half year results Kingboard Holdings (SEHK:148) has come into focus after reporting half year 2026 sales of HK$29,131.39 million and net income of HK$2,711.41 million, alongside declaring an interim dividend of HK$0.73 per share. At a latest share price of HK$52.35, Kingboard Holdings has seen mixed momentum, with a 1 day share price return of 4.18% and a 30 day share price return of 11.05%, while its 90 day share price return...

Some of the losses seen by insiders who purchased HK$223.5m worth of Kafelaku Coffee Holding Limited ( HKG:1869...

Despite the fact that Phoenix Media Investment (Holdings) Limited (HKG:2008) stock rose 14% last week, insiders who...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Why Jinhai Medical Technology’s Latest Half Year Results Matter Jinhai Medical Technology (SEHK:2225) has drawn fresh attention after reporting half year 2026 results. Sales reached SGD 34.02 million while the company reported a reduced net loss of SGD 4.36 million. For investors watching the stock in early September 2026, the combination of higher reported sales and a smaller loss compared with the prior year raises questions about how the business mix and cost base are evolving. Jinhai...

Why BYD Electronic (International) Stock Is Back in Focus BYD Electronic (International) (SEHK:285) is drawing fresh attention after its half year 2026 results showed sales of CNY 82,234.2 million, alongside a sharp drop in net income to CNY 426.33 million. The earnings announcement has arrived after a volatile stretch for BYD Electronic (International). The share price is up 6.84% on the day and has posted a 12.28% 1‑month share price return. However, it remains down 23.81% year to date and...

Why Fufeng Group stock is in focus after its half year results Fufeng Group (SEHK:546) has drawn fresh attention after its half year 2026 earnings report on 28 August showed net income and earnings per share significantly lower than a year earlier. The company also announced a semi annual dividend and provided an update on a recently completed share buyback tranche. These board decisions sit alongside the weaker earnings and give investors several moving pieces to assess at the same time. At...

Why Newborn Town stock is back on investor radar Newborn Town (SEHK:9911) has drawn fresh attention after reporting half year sales of US$606.86 million and net income of US$99.33 million, compared with US$442.85 million and US$68.11 million a year earlier. The recent half year earnings update and board reshuffle, including the appointment of Mr. Song Pengliang as an executive director, have arrived alongside a 10.83% 90 day share price return from Newborn Town and a 3 year total shareholder...

China Ruyi Holdings Limited recently reported results for the half year ended June 30, 2026, with sales of C¥1,183.08 million and net income of C¥837.41 million, both lower than the same period a year earlier. The decline in basic earnings per share from continuing operations to C¥0.05 highlights pressure on profitability despite the business remaining in the black. With earnings weaker year on year, we’ll now examine what this softer revenue performance means for China Ruyi’s broader...

Ruifeng Power Group half year earnings put recent share moves in context Ruifeng Power Group (SEHK:2025) has just reported half year 2026 earnings, giving investors fresh insight into how the cylinder block and head manufacturer is trading compared with the same period a year earlier. For the six months to June 30, 2026, the company reported sales of CNY 520.54 million versus CNY 550.18 million a year ago. Net income was CNY 15.7 million compared with CNY 17.35 million, with basic and diluted...

The renewed debate around Trump-era China tariffs is shining a light on where real capital is actually going. While some US industrials lean more on financial engineering, sections of China’s manufacturing base appear to stay closer to bricks, machines and factories. For investors, that opens up a fresh way to think about long-term exposure to industrial growth. This article walks through three Chinese manufacturing stocks that screen positively against this backdrop. The three stocks...

Why Air China’s Latest Half Year Earnings Matter For Investors Air China (SEHK:753) just reported half year 2026 earnings, with sales of CNY 89,267.62 million and a wider net loss of CNY 2,285.89 million. This mix of higher revenue and deeper losses gives investors fresh numbers to assess operational efficiency and cost control. Against this earnings backdrop, Air China’s share price closed at HK$3.84, with a 1-day share price return of 0.66% and a 7-day share price return of 1.86%. However,...

Akeso’s partner Summit Therapeutics reported that Akeso’s PD-1/VEGF bispecific ivonescimab achieved statistically significant overall survival gains over pembrolizumab and durvalumab in separate Phase III trials for PD-L1 positive non-small cell lung cancer and advanced biliary tract cancer, building on prior progression-free survival wins and recent China approvals. This string of head-to-head successes against current immunotherapy standards of care underscores ivonescimab’s potential to...